Antifungal use in HIV infection

REFERENCES

• KAPLAN JE, HANSON D, DWORKIN MS et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Chu. Infect. Dis. (2000) 30\(Suppl. 1):S5–14.
   Google Scholar
• MYLONAKIS E, BARLAM TF, FLANIGAN T, RICH JD: Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest (1998) 114 (1):251–262. •Comprehensive review of invasive aspergillosis in AIDS.
   Google Scholar
• MYLONAKIS E, RICH J, SKOLNIK PR, DE ORCHIS DF, FLANIGAN T: Invasive Aspergillus sinus/OS in patients with human immunodeficiency virus infection. Report of 2 cases and review. Medicine (Baltimore) (1997) 76(4):249–255.
   Google Scholar
• MYLONAKIS E, PALIOU M, SAX PE, SKOLNIK PR, BARON MJ, RICH JD: Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore) (2000) 79(4):269–280.
   Google Scholar
• DENNING DW, STEVENS DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect. Dis. (1990) 12(6):1147–1201.
   PubMedGoogle Scholar
• STEVENS DA, KAN VL, JUDSON MA et al.: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Chu. Infect. Dis. (2000) 30(4):696–709. ••Latest comprehensive guidelines, very wellreferenced.
   Google Scholar
• WHITE MH, ANAISSIE EJ, KUSNE S et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Chit. Infect. Dis. (1997) 24(4):635–642.
   PubMed Web of Science ®Google Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Chu. Infect. Dis. (1996) 22\(Suppl. 2):5133–144.
   Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl. J. Med. (1999) 340(10):764–771.
   Google Scholar
• DENNING DW: Diagnosis and management of invasive aspergillosis. Curr. Chu. Top. Infect. Dis. (1996) 16:277–299.
   PubMedGoogle Scholar
• DENNING DW, VENKATESWARLU K, OAKLEY KL etal.: Itraconazole resistance in Aspergillus fumigatus. Aritimicrob. Agents Chemother. (1997) 41(6):1364–1368.
   Google Scholar
• SCHIRALDI GF, CICERO SL, COLOMBO MD, ROSSATO D, FERRARESE M, SORESI E: Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br. j Dermatol (1996) 134\(Suppl. 46):25–29. Discussion 39–40.
   Google Scholar
• HOANG A: Caspofungin acetate: an antifungal agent. Am. j Health Syst. Pharm. (2001) 58(13):1206–1214. Quiz 1215–1207. ••Excellent and comprehensive review onthis new drug.
   Google Scholar
• PAPPAS PG, POTTAGE JC, POWDERLY WG et al.: Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. (1992) 116(10):847–853.
   PubMed Web of Science ®Google Scholar
• PATEL RG, PATEL B, PETRINI MF, CARTER RR, 3RD, GRIFFITH J: Clinical presentation, radiographic findings and diagnostic methods of pulmonary blastomycosis: a review of 100 consecutive cases. South. Med .j (1999) 92(3):289–295.
   PubMed Web of Science ®Google Scholar
• CHAPMAN SW BRADSHER RW, JR, CAMPBELL GD, JR, PAPPAS PG, KAUFFMAN CA: Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Chh. Infect. Dis. (2000) 30(4):679–683. •Latest guidelines by IDSA.
   Google Scholar
• COOK PP: Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole. South. Med. j (2001) 94(5):548–549.
   PubMed Web of Science ®Google Scholar
• CHOWFIN A, TIGHT R, MITCHELL S: Recurrent blastomycosis of the central nervous system: case report and review. Clin. Infect. Dis. (2000) 30(6):969–971.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. j Aritimicrob. Chemother (1993) 32(3):465–472.
   PubMed Web of Science ®Google Scholar
• DISMUKES WE, BRADSHER RW, JR, CLOUD GC et al: Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am. j Med (1992) 93(5)489–497.
   Google Scholar
• LI RK, CIBLAK MA, NORDOFF N, PASARELL L, WARN OCK DW, MCGINNIS MR: In vitro activities of voriconazole, itraconazole and amphotericin B against Blastomyces dermatitidis, Coccidiaides immitis and Histoplasma capsulatum. Aritimicrob. Agents Chemother (2000) 44(6):1734–1736.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of In vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. I Chu. Microbial (1998) 36(10):2950–2956.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, BRADSHER RW, KAUFFMAN CA et al.: Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Chu. Infect. Dis. (1997) 25(2):200–205.
   Google Scholar
• DAROUICHE RO: Oropharyngeal and oesophageal candidiasis in immunocompromised patients: treatment issues. Chu. Infect. Dis. (1998) 26(2):259–272. Quiz 273–254. ••Comprehensive, well written review.
   Google Scholar
• PATTON LL, BONITO AJ, SHUGARS DA: A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg. Oral Med. Oral Ratite]. Oral Radial. Ended. (2001) 92(2):170–179.
   PubMed Web of Science ®Google Scholar
• REX JH, WALSH TJ, SOBEL JD etal.: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Chu. Infect. Dis. (2000) 30(4):662–678.
   Google Scholar
• ALLY R, SCHURMANN D, KREISEL W et al.: A randomised, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of oesophageal candidiasis in immunocompromised patients. Chu. Infect. Dis. (2001) 33(9):1447–1454.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A, ARATHOON EG, GOTUZZO E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomised double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Chu. Infect. Dis. (2001) 33(9):1529–1535.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A, GOTUZZO E, ARATHOON E et al.: The efficacy, safety and tolerability of caspofungin vs. fluconazole in the treatment of oesophageal candidiasis. 41st Interscierice Conference on Antimicrobial Agents and Chemotherapy. September and December 2001. (2001):376. Abstract J–675.
   Google Scholar
• FICHTENBAUM CJ, KOLETAR S, YIANNOUTSOS C et al.: Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Chu. Infect. Dis. (2000) 30(5):749–756. •Worth reading if you encounter this problem.
   Google Scholar
• POWDERLY WG, FINKELSTEIN D, FEINBERG J et al: A randomised trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl. Med. (1995) 332(11):700–705.
   PubMed Web of Science ®Google Scholar
• MARTINS MD, LOZANO-CHIU M, REX JH: Declining rates of oropharyngeal candidiasis and carriage of Candida albicaris associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicaris in human immunodeficiency virus-infected patients. Chu. Infect. Dis. (1998) 27(5):1291–1294.
   PubMed Web of Science ®Google Scholar
• MYLONAKIS E, FLANIGAN TP: Antifungal prophylaxis with weekly fluconazole for patients with AIDS. Chu. Infect. Dis. (1998) 27(6):1376–1378.
   PubMed Web of Science ®Google Scholar
• Coccidioidomycosis - Arizona, 1990-1995. MMWR Marb. Mort. Wkly Rep. (1996) 45(49):1069–1073.
   PubMedGoogle Scholar
• WOODS CW, MCRILL C, PLIKAYTIS BD et al.: Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994–1997: incidence, risk factors and prevention. j Infect. Dis. (2000) 181 (4):1428–1434. •Excellent paper on the epidemiology of coccidioidomycosis.
   Google Scholar
• AMPEL NM, DOLS CL, GALGIANI JN: Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am. j Med. (1993) 94(3):235–240.
   PubMed Web of Science ®Google Scholar
• GALGIANI JN, CATANZARO A, CLOUD GA et al.: Comparison of oral fluconazole and itraconazole for progressive, non-meningeal coccidioidomycosis. A randomised, double-blind trial. Mycoses Study Group. Ann. Intern. Med. (2000) 133(9):676–686.
   Google Scholar
• GALGIANI JN, AMPEL NM, CATANZARO A, JOHNSON RH, STEVENS DA, WILLIAMS PL: Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Chu. Infect. Dis. (2000) 30(4):658–661. •Latest guidelines, good references.
   Google Scholar
• GALGIANI JN, CATANZARO A, CLOUD GA etal.: Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann. Intern. Med. (1993) 119(1):28–35.
   Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK etal.: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45(6):1854–1859.
   Google Scholar
• MARQUES SA, ROBLES AM, TORTORANO AM, TUCULET MA, NEGRONI R, MENDES RP: Mycoses associated with AIDS in the Third World. Med. Mycology (2000) 38\(Suppl. 1):269- •• •Good review of data concerning invasive mycosis in the Third World.
   Google Scholar
• SAAG MS, GRAYBILL RJ, LARSEN RA et al.: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):710–718. ••Outstanding review and latest guidelines.
   Google Scholar
• VISNEGARWALA F, GRAVISS EA, LACKE CE et al.: Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin. Infect. Dis. (1998) 27(5):1231–1237. •Relevant clinical information outlining the predictive factors associated with cryptococcal infection in this population.
   Google Scholar
• VAN DER HORST CM, SAAG MS, CLOUD GA et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl. j Med (1997) 337(1):15–21. •A classic paper.
   Google Scholar
• SAAG MS, CLOUD GA, GRAYBILL JR etal.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. (1999) 28(2):291–296.
   Google Scholar
• LARSEN RA, BOZZETTE SA, JONES BE et al.: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1994) 19(4):741–745.
   PubMed Web of Science ®Google Scholar
• LEENDERS AC, REISS E PORTEGIES P et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS (1997) 11(12):1463–1471.
   Google Scholar
• ABERG JA, WATSON J, SEGAL M, CHANG LW: Clinical utility of monitoring serum cryptococcal antigen (scrag) titers in patients with aids-related cryptococcal disease. HIV Clin. Trials. (2000) 1(1):1–6.
   PubMedGoogle Scholar
• ESPINEL-INGROFF A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. j Clin. Microbial. (1998) 36(1):198–202.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ et al: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Aritimicrob. Agents Chemother. (1997) 41(11):2333–2338.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, GARCIA-VIEJO MA, MARCOS MA et al.: Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS (2000) 14(16):2615–2617.
   PubMed Web of Science ®Google Scholar
• RODERO L, CORDOBA S, CAHN P et al.: In vitro susceptibility studies of Cryptocaccus neaformans isolated from patients with no clinical response to amphotericin B therapy. j Aritimicrob. Chemother (2000) 45(2):239–242. •Relevant microbiological data on in vitro susceptibility of clinical isolates of C. neoformans that may influence future approach to management.
   Google Scholar
• ALLER Al, MARTIN-MAZUELOS E, LOZANO F et al.: Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Aritimicrob. Agents Chemother (2000) 44(6):1544–1548.
   PubMed Web of Science ®Google Scholar
• DAVEY KG, JOHNSON EM, HOLMES AD, SZEKELY A, WARNOCK DW: In-vitro susceptibility of Cryptocaccus neaformans isolates to fluconazole and itraconazole. j Aritimicrob. Chemother (1998) 42(2):217–220.
   PubMed Web of Science ®Google Scholar
• MONDON P, PETTER R, AMALFITANO G et al.: Heteroresistance to fluconazole and voriconazole in Cryptocaccus neaformans Antimicrob. Agents Chemother (1999) 43(8):1856–1861.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, SOBEL J, SAAG M et al.: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. (2000) 30(1):47–54.
   PubMed Web of Science ®Google Scholar
• MYLONAKIS E, MERRIMAN NA, RICH JD et al.: Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diag. Microbial Infect. Dis. (1999) 34(2):111–114.
   PubMed Web of Science ®Google Scholar
• PARK MK, HOSPENTHAL DR, BENNETT JE: Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin. Infect. Dis. (1999) 28(3):629–633.
   PubMed Web of Science ®Google Scholar
• WHEAT J: Endemic mycoses in AIDS: a clinical review. Clin. Microbial Rev (1995) 8(1):146–159.
   PubMed Web of Science ®Google Scholar
• WHEAT J, SAROSI G, MCKINSEY D et al.: Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):688–695. ••Excellent review with latest guidelinesfrom the Infectious Diseases Society of America.
   Google Scholar
• WHEAT LJ, CLOUD G, JOHNSON PC etal.: Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Aritimicrob. Agents Chemother. (2001) 45(8):2354–2357.
   Google Scholar
• WHEAT J, HAFNER R, KORZUN AH et al.: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am. I Med (1995) 98(4):336–342.
   Google Scholar
• WHEAT J, MAWHINNEY S, HAFNER R etal.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am. J. Med. (1997) 103(3):223–232.
   Google Scholar
• WHEAT LJ, CONNOLLY P, SMEDEMA M, BRIZENDINE E, HAFNER R: Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin. Infect. Dis. (2001) 33(10:1910–1913.
   PubMedGoogle Scholar
• GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER MF, RINALDI MG: Treatment of histoplasmosis with MK-991 (L-743,872). Aritimicrob. Agents Chemother (1998) 42(1):151–153.
   PubMed Web of Science ®Google Scholar
• KOHLER S, WHEAT LJ, CONNOLLY P etal.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Aritimicrob. Agents Chemother (2000) 44(7):1850–1854.
   Google Scholar
• MCKINSEY DS, WHEAT LJ, CLOUD GA eta].: Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomised, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. (1999) 28(5):1049–1056.
   Google Scholar
• LORTHOLARY 0, DENNING DW, DUPONT B: Endemic mycoses: a treatment update. j Antimicrob. Chemother (1999) 43(3):321–331.
   PubMed Web of Science ®Google Scholar
• BENARD G, DUARTE AJ: Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases. Clin. Infect. Dis. (2000) 31(4):1032–1039. •Latest comprehensive review on paracoccidioidomycosis in AIDS.
   Google Scholar
• KARP CL, NEVA FA: Tropical infectious diseases in human immunodeficiency virus-infected patients. Clin Infect. Dis. (1999) 28(5):947–963. Quiz 964–945.
   Google Scholar
• HAHN RC, HAMDAN JS: In vitro susceptibilities of Paracoccidioides brasiliensis yeast form to antifungal drugs. Mycoses (2000) 43(11-12):403–407.
   PubMed Web of Science ®Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA, FOTHERGILL AW, COOPER CR, JR, RINALDI MG: In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. (1997) 41(8):1832–1834.
   PubMed Web of Science ®Google Scholar
• NARANJO MS, TRUJILLO M, MUNERA MI, RESTREPO P, GOMEZ I, RESTREPO A: Treatment of paracocc-idioidomycosis with itraconazole. j Med. Vet. Mycol. (1990) 28 (1):67–76.
   PubMedGoogle Scholar
• TOBON AM, OROZCO B, ESTRADA S et al.: Paracoccidioidomycosis and AIDS: report of the first two Colombian cases. Rev Inst. Med. Trop. Sao Paulo (1998) 40(6):377–381.
   PubMedGoogle Scholar
• SIRISANTHANA T, SUPPARATPINYO K, PERRIENS J, NELSON KE: Amphotericin B and itraconazole for treatment of disseminated Perlicillium marneffei infection in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (1998) 26(5):1107–1110. ••Outstanding guideline setting study fromthe main group reporting on penicilliosis.
   Google Scholar
• SUPPARATPINYO K, PERRIENS J, NELSON KE, SIRISANTHANA T: A controlled trial of itraconazole to prevent relapse of Perlicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl. I Med. (1998) 339(24):1739–1743.
   PubMed Web of Science ®Google Scholar
• DUONG TA: Infection due to Perlicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin. Infect. Dis. (1996) 23 (1) : 125–130. •Comprehensive clinical review on penicilliosis.
   Google Scholar
• IMWIDTHAYA P, THIPSUVAN K, CHAIPRASERT A, DANCHAIVIJITRA S, SUTTHENT R, JEARANAISILA-VONG J: Penicillium marneffet types and drug susceptibility. Mycopathologia (2001) 149 (3) : 109–115.
   PubMed Web of Science ®Google Scholar
• CHARIYALERTSAK S, SUPPARATPINYO K, SIRISANTHANA T, NELSON KE: A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. D (2002) 34(2):277–284.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3792b2_02_FDA-voriconazole.pdf FDA CFDEAR, Division of Special Pathogen and Immunologic Drug Products: Background document for the antiviral drug products advisory committee meeting: (voriconazole tablets), (voriconazole injection), Pfizer Global Research & Development, NDAs 21–266 and 21–267. (2001) 1–56.
   Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3676b1 .htm FDA CFDEAR, Division of Special Pathogen and Immunologic Drug Products: Background document for antiviral drug products advisory committee meeting: CANCIDAS" (Caspofungin acetate for intravenous injection) Merck Corporation NDA 21–227. (2001) 1–33.
   Google Scholar